KeithWilliamPratzMD

Associate Professor of Medicine, Director of Leukemia, University of Pennsylvania

Dr. Pratz is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2006 - 2009
Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 2002 - 2005
Rutgers Robert Wood Johnson Medical SchoolClass of 2002

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013

PubMed

Evolving racial/ethnic disparities in AML survival in the novel therapy era.
Xin Wang, Phyllis A Gimotty, Andrew H Matthews, Ronac Mamtani, Selina M Luger
Blood Advances. 2025-02-11
The impact of post-remission granulocyte colony-stimulating factor use in the phase 3 studies of venetoclax combination treatments in patients with newly diagnosed acu...
Courtney D DiNardo, Keith W Pratz, Panayiotis Panayiotidis, Xudong Wei, Vladimir Vorobyev
American Journal of Hematology. 2025-01-01
Tumor Lysis Syndrome in Acute Myeloid Leukemia Patients Treated With a Venetoclax Based Regimen.
Margaret Rowe, Daria Babushok, Martin Carroll, Alison Carulli, Noelle Frey
European Journal of Haematology. 2024-12-26

Journal Articles

Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia
Courtney D Dinardo, Brian A Jonas, Jacqueline S Garcia, Anthony Letai, Wan-Jen Hong, Keith W Pratz, The New England Journal of Medicine
Venetoclax Combined with Decitabine or Azacitidine in Treatment-Naive, Elderly Patients with Acute Myeloid Leukemia
Brian A Jonas, Courtney D DiNardo, Olga Frankfurt, Daniel A Pollyea, Keith Pratz, Anthony Letai, Martha Arellano, Marina Konopleva, Hagop M Kantarjian, Blood

Abstracts/Posters

Fried Frailty Phenotype Predicts Mortality for Newly Diagnosed Older Patients with Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
Keith W. Pratz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Venetoclax in Combination with Gilteritinib in Patients with Relapsed/Refractory Acute Myeloid Leukemia: A Phase 1b StudyClinically Relevant Abstract
Keith W. Pratz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Phase II Randomized Trial of Gilteritinib Vs Midostaurin in Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML)
Keith W. Pratz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Coagulopathy, Hypoxemia, and Mortality Outcomes in Newly Diagnosed Acute Myeloid Leukemia with Hyperleukocytosis Treated with Large Volume Leukapheresis
Keith W. Pratz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Maintenance Decitabine (DAC) Improves Disease-Free (DFS) and Overall Survival (OS) after Intensive Therapy for Acute Myeloid Leukemia (AML) in Older Adults, Particular...
Keith W. Pratz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Join now to see all

Lectures

Management of Neutropenia during Venetoclax-Based Combination Treatment in Patients with Newly Diagnosed Acute Myeloid Leukemia
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
New Therapies for Better Patient Outcomes in Acute Myeloid Leukemia: Integration of Recent Data Sets Into Clinical Practice
60th American Society of Hematology Annual Meeting - 11/30/2018

Azacitidine and Venetoclax in Previously Untreated Acute Myeloid LeukemiaAugust 2020
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid LeukemiaAugust 2020
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid LeukemiaAugust 2020
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid LeukemiaAugust 2020
Join now to see all